Erasca faces class action lawsuit
Analysis based on 6 articles · First reported May 19, 2026 · Last updated Jun 11, 2026
The class action lawsuit against Erasca>>> and the allegations of patent infringement by Revolution Medicines>>> have caused a significant decline in Erasca>>>'s share price, directly impacting its investors. This event highlights the risks associated with intellectual property disputes in the biotechnology sector, potentially leading to increased scrutiny of similar companies.
A class action lawsuit has been filed against Erasca>>> by Bragar Eagel & Squire>>> on behalf of stockholders who purchased common stock between January 14, 2025, and April 26, 2026. The lawsuit alleges that Erasca>>> made false and misleading statements and/or failed to disclose material adverse facts, specifically concerning its ERAS-0015 drug. These allegations stem from a letter Erasca>>> received from Revolution Medicines>>>, claiming that ERAS-0015 infringes on a Revolution Medicines>>> patent and involves trade secret misappropriation. Following this disclosure on April 28, 2026, Erasca>>>'s share price plummeted by approximately 48%, from $19.15 to $9.90 per share. Bragar Eagel & Squire>>> partners Brandon Walker>>> and Melissa Fortunato>>> are encouraging affected investors to join the lawsuit, which was filed in the United States — United States District Court for the Southern District of California>>>.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard